7CA.F Camurus AB (publ)

Healthcare Biotechnology Frankfurt Exchange
65.60 EUR
Close of Nov 12, 2026
40.60 67.70
Market cap
EUR 3.90B
P/E
56.6x
P/B
8.91x
ROE
17.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 7CA.F undervalued?

Graham number

The Graham number of Camurus AB (publ) cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Camurus AB (publ) fundamental analysis

No fundamental analysis for Camurus AB (publ) yet.

Camurus AB (publ) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Camurus AB (publ)

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and…

Full company profile